key: cord-0314414-qpkx9pde
authors: Li, R.; Liu, H.; Fairley, C. K.; Ong, J. J.; Guo, Y.; Zou, Z.; Xie, L.; Zhuang, G.; Li, Y.; Shen, M.; Zhang, L.
title: mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia
date: 2022-05-10
journal: nan
DOI: 10.1101/2022.05.08.22274797
sha: a678d4d103391b187c4ef8e7f4e1897c597ce9f6
doc_id: 314414
cord_uid: qpkx9pde

Background: Australia implemented an mRNA-based booster vaccination strategy against the COVID-19 Omicron variant in November 2021. We aimed to evaluate the effectiveness and cost-effectiveness of the booster strategy over 180 days. Methods: We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy (administered 3 months after 2nd dose) in those aged [≥]16 years in Australia from a healthcare system perspective. The willingness-to-pay threshold was chosen as A$ 50,000. Findings: Compared with 2-doses of COVID-19 vaccines without a booster, Australia's booster strategy would incur an additional cost of A$0.88 billion but save A$1.28 billion in direct medical cost and gain 670 quality-adjusted life years (QALYs) in 180 days of its implementation. This suggested the booster strategy is cost-saving, corresponding to a benefit-cost ratio of 1.45 and a net monetary benefit of A$0.43 billion. The strategy would prevent 1.32 million new infections, 65,170 hospitalisations, 6,927 ICU admissions and 1,348 deaths from COVID-19 in 180 days. Further, a universal booster strategy of having all individuals vaccinated with the booster shot immediately once their eligibility is met would have resulted in a gain of 1,599 QALYs, a net monetary benefit of A$1.46 billion and a benefit-cost ratio of 1.95 in 180 days. Interpretation: The COVID-19 booster strategy implemented in Australia is likely to be effective and cost-effective for the Omicron epidemic. Universal booster vaccination would have further improved its effectiveness and cost-effectiveness.

The model consisted of 11 health states capturing the disease progression of COVID-19 ( Figure S1 ). A 115 vaccinated individual may be infected by SARS-CoV-2 and enter a 'latent infection state'. After a mean 116 incubation period of 5.2 (4. 1-7.0 ) days 24 , about 83% of infected individuals developed symptoms 25 , and the 117 remaining asymptomatic infections would spontaneously recover. A symptomatic infection might first exhibit 118 'mild/moderate' symptoms. They might then 'recover' or deteriorate to a 'severe' state. A patient in the 'severe' 119 state might 'recover' or progress to the 'critical' state. Similarly, a patient in the 'critical' state might 'recover' or 120 'die'. Transition probabilities between states were estimated using the formula = 1 − − , where r denoted 121 daily transition rate 25 . The basic model cycle length was 1 day, with a half-cycle correction applied. 

The costs of booster vaccination included the costs of the mRNA-based vaccine in Australia (A$53/dose) and 142 the vaccination administration ($20/dose) 28, 29 . The cost of PCR tests and rapid antigen self-test for COVID-19 143 infection was estimated to be A$85 and A$13 per person, respectively 30,31 . In addition, we collected the costs of 144 general practitioner (GP) consultation, general hospitalisation and ICU admission from published literature 32-34 .

The cost of medical services varied across clinical disease stages 25,35-37 , and we calculated the total direct medical 146 cost of COVID-19 cases with varied severity by multiplying the unit cost of the medical services by the duration 147 of each disease stage (Appendix 1.5).Health utility scores for COVID-19 patients were derived from the disutility 148 weights of severe lower respiratory tract infection 38,39 and the estimates of pricing models for COVID-19 149 treatments published by the Institute for Clinical and Economic Review 40 (Appendix 1.6).

We assumed a discount rate of 3% (0-6%) annually for both cost and quality-adjusted life-years (QALYs). We 152 calculated the incremental costs and incremental QALYs for booster vaccination strategy compared with no 153 booster (counterfactual scenario). The incremental cost-effectiveness ratio (ICER) was defined as the 154 incremental cost per QALY gained. We used a willingness-to-pay (WTP) threshold of ICER<A$50,000. We 

Our study suggests the vaccination booster strategy is practical for COVID-19 prevention and control in 253 Australia. To date, Australia has fully opened its borders, removing most social-distancing restrictions (such as 254 city lockdown) and the requirement of facial masks in most public areas, including indoors. Contact tracing and estimation based on real-world data. Second, we assumed that the efficacy of COVID-19 vaccines begins to 270 wane in 3 months. In reality, the efficacy of vaccines is more likely to gradually decline without a clear cut-off.

This assumption may have led to an overestimate of vaccine efficacy in the short term, and an underestimate in 272 the long term. Third, we did not consider the other non-mRNA-based COVID-19 vaccines (e.g., AstraZeneca or 273 Novavax) in Australia. However, AstraZeneca is no longer recommended for use as the booster dose for people 274 who received a primary vaccination course of the AstraZeneca COVID-19 vaccine, and Novavax is rarely used 275 (<1%) in Australia. Finally, given limited public health resources and escalating health inequity during the 276 pandemic, there is a need for more targeted, local-based vaccine and booster distribution strategies that can 277 achieve a tradeoff between cost-effectiveness and equity. The design of such strategies, while beyond the scope 278 of this work, will be critical in alleviating the burden of COVID-19, reducing health care costs, and achieving 279 equity.

In conclusion, Australia's current COVID-19 booster strategy is likely to be effective and cost-effective for 282 curbing this Omicron epidemic. Further, achieving a universal booster vaccination would have improved its 283 effectiveness and cost-effectiveness.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 10, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 10, 2022. ; https://doi.org/10.1101/2022.05.08.22274797 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 10, 2022. ; https://doi.org/10.1101/2022.05.08.22274797 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 10, 2022. ; https://doi.org/10.1101/2022.05.08.22274797 doi: medRxiv preprint

Economic burden of COVID-19, China

The Economic Implications of COVID-19 in the United 44

Antiviral pills could change pandemic's course

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company 417 reports

efficacy and safety of three new oral antiviral treatment (molnupiravir, 419 fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

African clinical trial denied access to key COVID drug Paxlovid

Increased risk of SARS-CoV-2 reinfection 423 associated with emergence of Omicron in South Africa

emergence and phenotypic characterisation of the global 425 SARS-CoV-2 C.1.2 lineage

Defining the risk of SARS-CoV-2 variants on immune